AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32737717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (150 mg) and Ipatasertib (300 mg) in Arm B
Number of subjects: 66
Study 32737717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cobimetinib and Ipatasertib
Number of subjects: 66
Study 32737717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic analyses
Number of subjects: 66
Study 32738041 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) therapy
Number of subjects: 122
Study 32738041 — intervention group
Group type: COMPARATOR
Intervention: Control (no rhPTH(1-84))
Number of subjects: 122
Study 32738042 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-mg subcutaneous leuprolide acetate (0.375 mL) at 0 and 24 weeks
Number of subjects: 64
Study 32738255 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-based immunodetection assay (in-cell ELISA) for quantifying SARS-CoV-2 infection.
Number of subjects: 0
Study 32738255 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (staining plaques or foci, PCR) for detecting SARS-CoV-2 infection.
Number of subjects: 0
Study 32738404 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive atrial pacing (CAP)
Number of subjects: 5379
Study 32738404 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-triggered AT/AF
Number of subjects: 5379
Study 32738404 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous AT/AF
Number of subjects: 5379
Study 32738543 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC procedure training model
Number of subjects: 4
Study 32738543 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC procedure publications
Number of subjects: 4
Study 32738543 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict of interest in studies
Number of subjects: 4
Study 32738543 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled training model
Number of subjects: 4
Study 32738543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical implications of industry involvement
Number of subjects: 4
Study 32738823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 60
Study 32738880 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff education programme about person-centred care and promotion of thriving (14-month duration)
Number of subjects: 0
Study 32738880 — intervention group
Group type: COMPARATOR
Intervention: One-hour lecture for staff (Control)
Number of subjects: 0
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic arteriosclerosis assessed by carotid femoral artery pulse wave velocity (CF-PWV) > 12 m/s
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-site atherosclerotic plaques (MAP)
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-PWV > 12 m/s
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Male
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic agents
Number of subjects: 1178
Study 32738905 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1178
Study 32738928 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 32739261 — intervention group
Group type: EXPERIMENTAL
Intervention: PHVD
Number of subjects: 4216
Study 32739261 — intervention group
Group type: COMPARATOR
Intervention: Hemorrhage without ventricular dilatation
Number of subjects: 4216
Study 32739261 — intervention group
Group type: COMPARATOR
Intervention: Normal head ultrasound
Number of subjects: 4216
Study 32739261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for progressive dilatation
Number of subjects: 4216
Study 32739261 — intervention group
Group type: COMPARATOR
Intervention: No intervention for progressive dilatation
Number of subjects: 4216
Study 32739453 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarctation of the aorta
Number of subjects: 3538
Study 32739453 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated aortic valve disease
Number of subjects: 3538
Study 32739453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanotic heart disease
Number of subjects: 3538
Study 32739453 — intervention group
Group type: EXPERIMENTAL
Intervention: Eisenmenger syndrome
Number of subjects: 3538
Study 32739654 — intervention group
Group type: EXPERIMENTAL
Intervention: Saizen® administered via easypod™
Number of subjects: 86
Study 32740083 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 (7α-hydroxy-4-cholesten-3-one)
Number of subjects: 71
Study 32740083 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF19
Number of subjects: 71
Study 32740096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided gastroenterostomy (EUS-GE)
Number of subjects: 23
Study 32740096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided gastroenterostomy (EUS-GE) with misdeployed lumen-apposing metal stent
Number of subjects: 23
Study 32740125 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV reactivation post-LVAD implantation
Number of subjects: 349
Study 32740125 — intervention group
Group type: COMPARATOR
Intervention: CMV reactivation
Number of subjects: 349
Study 32740129 — intervention group
Group type: EXPERIMENTAL
Intervention: Small intrapericardial centrifugal LVAD
Number of subjects: 0
Study 32740129 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 0
Study 32740181 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote telesimulation with standardized parents (90-minute Skype sessions)
Number of subjects: 79
Study 32740184 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous newborn infant parasympathetic evaluation score
Number of subjects: 32
Study 32740184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean newborn infant parasympathetic evaluation score
Number of subjects: 32
Study 32740184 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort Behavior scores
Number of subjects: 32
Study 32740221 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 16
Study 32740343 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal LVAD implantation via thoracotomy
Number of subjects: 0
Study 32740343 — intervention group
Group type: COMPARATOR
Intervention: Medical Management arm
Number of subjects: 0
Study 32740508 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma Treatment Compliance Assessment Tool (GTCAT)
Number of subjects: 0
Study 32740873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale (FSS)
Number of subjects: 62
Study 32740873 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS-Depression, PSQI, and ACTIVLIM
Number of subjects: 62
Study 32740873 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor fatigability tests (6-min Walk Test and isometric muscular fatigability test)
Number of subjects: 62
Study 32741045 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-directed goal setting incorporating blood glucose monitoring (BGM), continuous glucose monitoring (CGM), and insulin dosing
Number of subjects: 122
Study 32741045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sessions where goal intentions focused on BG only (without addressing insulin or CGM)
Number of subjects: 122
Study 32741045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sessions where goal intentions focused on insulin dosing only (without addressing BGM or CGM)
Number of subjects: 122
Study 32741616 — intervention group
Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) in KIR AA mothers
Number of subjects: 204
Study 32741616 — intervention group
Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) in KIR AB mothers
Number of subjects: 204
Study 32741616 — intervention group
Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) in KIR BB mothers
Number of subjects: 204
Study 32741616 — intervention group
Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) with oocyte donation in KIR AA patients
Number of subjects: 204
Study 32741616 — intervention group
Group type: COMPARATOR
Intervention: Elective single embryo transfer (SET)
Number of subjects: 204
Study 32741616 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased embryo HLA-C2 load in KIR AA patients
Number of subjects: 204
Study 32741616 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of HLA-C1 over HLA-C2 donors
Number of subjects: 204
Study 32741971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3127804 monotherapy (4, 8, 12, 16, 20 and 27 mg/kg)
Number of subjects: 62
Study 32741971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3127804 (8, 12, 16, 20 and 27 mg/kg) with 8 mg/kg ramucirumab
Number of subjects: 62
Study 32741971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3127804 (20 mg/kg) with 12 mg/kg ramucirumab
Number of subjects: 62
Study 32741971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (LY3127804 with ramucirumab)
Number of subjects: 62
Study 32741971 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3127804 20 mg/kg
Number of subjects: 62
Study 32742241 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin-labeled molecular probes comprising specific regions of the SARS-CoV-2 spike; yields from transient transfection ranged from ~0.5 mg/L for the complete ectodomain to >5 mg/L for several subregions.
Number of subjects: 2
Study 32742241 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated probes; characterized for antibody-binding specificities and cell-sorting capabilities.
Number of subjects: 2
Study 32742443 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with oral etoposide and cisplatin
Number of subjects: 68
Study 32742443 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy
Number of subjects: 68
Study 32742443 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 68
Study 32742711 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar recombinant follicle stimulating hormone (rFSH)
Number of subjects: 1222
Study 32743009 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced spirometry
Number of subjects: 1988
Study 32743009 — intervention group
Group type: COMPARATOR
Intervention: Body plethysmography
Number of subjects: 1988
Study 32743011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular administration of Tranexamic Acid (TXA) 100 mL (30 mg/mL)
Number of subjects: 47
Study 32743011 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IA injection of TXA)
Number of subjects: 47
Study 32743011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular administration of Tranexamic Acid (TXA)
Number of subjects: 47
Study 32743079 — intervention group
Group type: EXPERIMENTAL
Intervention: PS/EF CCT
Number of subjects: 90
Study 32743079 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal CCT
Number of subjects: 90
Study 32743079 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90
Study 32743692 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based self-monitored mood
Number of subjects: 206
Study 32743692 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based self-monitored activity
Number of subjects: 206
Study 32743756 — intervention group
Group type: EXPERIMENTAL
Intervention: UKA with patella denervation (PD)
Number of subjects: 66
Study 32743756 — intervention group
Group type: COMPARATOR
Intervention: UKA without patella denervation (no-PD)
Number of subjects: 66
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotics
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensives
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence (self-reported)
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C control
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c control (for diabetic patients)
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 664
Study 32743852 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 664
Study 32744105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 367
Study 32744105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment in patients with definite/probable FH
Number of subjects: 367
Study 32745296 — intervention group
Group type: EXPERIMENTAL
Intervention: Community stigma
Number of subjects: 1888
Study 32745296 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalised stigma
Number of subjects: 1888
Study 32745296 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor ART adherence
Number of subjects: 1888
Study 32745296 — intervention group
Group type: EXPERIMENTAL
Intervention: Health setting stigma
Number of subjects: 1888
Study 32745512 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-line health-care workers
Number of subjects: 2135190
Study 32745512 — intervention group
Group type: COMPARATOR
Intervention: General community
Number of subjects: 2135190
Study 32745961 — intervention group
Group type: EXPERIMENTAL
Intervention: ssCART-19s (CAR-T therapy targeting CD19 with shRNA-IL-6 gene silencing)
Number of subjects: 3
Study 32746802 — intervention group
Group type: EXPERIMENTAL
Intervention: PartoSure® test
Number of subjects: 400
Study 32746820 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD
Number of subjects: 5728
Study 32746839 — intervention group
Group type: EXPERIMENTAL
Intervention: ppRx with immunotherapy or targeted therapy
Number of subjects: 0
Study 32746839 — intervention group
Group type: COMPARATOR
Intervention: Other treatments after progression
Number of subjects: 0
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Before the discovery of the causal mutation in 1996
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: After the introduction of genetic testing in 1996
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with non-neurological presentation after 1996
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with neurological presentation after 1996
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with late-onset FRDA
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with typical onset (age < 25 years)
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of age at onset with GAA repeat length (GAA1) in neurological onset cases
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of age at onset with GAA repeat length (GAA1) in non-neurological presentation
Number of subjects: 611
Study 32746884 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in age at onset among 54 siblings' pairs
Number of subjects: 611
Study 32746893 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity trackers (Fitbit Charge HR2) during weeks with gout flares
Number of subjects: 44
Study 32746893 — intervention group
Group type: COMPARATOR
Intervention: Wearable activity trackers (Fitbit Charge HR2) during non-flare periods
Number of subjects: 44
Study 32746893 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity trackers (Fitbit Charge HR2)
Number of subjects: 44
Study 32747077 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane general anaesthesia
Number of subjects: 589
Study 32747075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital intubation
Number of subjects: 4509
Study 32747075 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital intubation
Number of subjects: 4509
Study 32747205 — intervention group
Group type: EXPERIMENTAL
Intervention: nutritionDay 2.0 audit and feedback intervention
Number of subjects: 0
Study 32747205 — intervention group
Group type: EXPERIMENTAL
Intervention: nutritionDay 2.0 tools
Number of subjects: 0
Study 32747357 — intervention group
Group type: EXPERIMENTAL
Intervention: cAMB administered at 1.0 g per day
Number of subjects: 0
Study 32747357 — intervention group
Group type: EXPERIMENTAL
Intervention: cAMB administered at 1.5 g per day
Number of subjects: 0
Study 32747357 — intervention group
Group type: EXPERIMENTAL
Intervention: cAMB administered at 2.0 g per day
Number of subjects: 0
Study 32747469 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell therapy (tumor-infiltrating lymphocytes, TILs)
Number of subjects: 0
Study 32747469 — intervention group
Group type: COMPARATOR
Intervention: Previous progression on anti-CTLA-4 therapy
Number of subjects: 0
Study 32747693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayton risk tool
Number of subjects: 971
Study 32747693 — intervention group
Group type: COMPARATOR
Intervention: Balkus risk tool
Number of subjects: 971
Study 32747953 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation (PPI)
Number of subjects: 704
Study 32747953 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) at discharge
Number of subjects: 704
Study 32747953 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative AF
Number of subjects: 704
Study 32748394 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure (BP)
Number of subjects: 536607
Study 32748394 — intervention group
Group type: COMPARATOR
Intervention: Korotkoff phase IV (K4) technique for diastolic BP measurement
Number of subjects: 536607
Study 32748394 — intervention group
Group type: COMPARATOR
Intervention: CRADLE device (semi-automated BP monitor)
Number of subjects: 536607
Study 32748658 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activity energy expenditure
Number of subjects: 20
Study 32748658 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity duration
Number of subjects: 20
Study 32748658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 20
Study 32748658 — intervention group
Group type: EXPERIMENTAL
Intervention: Light activity time
Number of subjects: 20
Study 32748666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive augmented mobility program (CAMP)
Number of subjects: 0
Study 32748789 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut PRO transcatheter heart valve (23, 26, or 29 mm)
Number of subjects: 629
Study 32749224 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based positive psychological intervention (¡Alégrate!) for 5 weeks.
Number of subjects: 70
Study 32749224 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (3 times weekly emotion reporting).
Number of subjects: 70
Study 32749224 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based positive psychological intervention (¡Alégrate!).
Number of subjects: 70
Study 32749710 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment (direct-acting antivirals)
Number of subjects: 2167
Study 32749716 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective natural history study
Number of subjects: 35
Study 32749716 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective deep phenotyping and detailed variant analysis
Number of subjects: 35
Study 32749995 — intervention group
Group type: EXPERIMENTAL
Intervention: More Stamina mobile app for fatigue self-management
Number of subjects: 60
Study 32749995 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study 32749998 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mental health intervention
Number of subjects: 0
Study 32749998 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32750290 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased HRV index ≤ median (14.29)
Number of subjects: 1922
Study 32750290 — intervention group
Group type: COMPARATOR
Intervention: Standard HRV parameters (HRV triangular index, SD of normal-to-normal intervals, square root of mean squared differences of successive normal-to-normal intervals, mean heart rate)
Number of subjects: 1922
Study 32750295 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Ec-SOD activity in patients with normal LV geometry
Number of subjects: 1047
Study 32750295 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Ec-SOD activity in patients with abnormal LV geometry without HF
Number of subjects: 1047
Study 32750295 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Ec-SOD activity in patients with abnormal LV geometry and overt HF
Number of subjects: 1047
Study 32750311 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born preterm
Number of subjects: 126
Study 32750486 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 121
Study 32750486 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF with diabetes
Number of subjects: 121
Study 32750486 — intervention group
Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 121
Study 32750501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy without pelvic lymph node dissection
Number of subjects: 395
Study 32750501 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN frozen section assessment
Number of subjects: 395
Study 32750501 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN biopsy
Number of subjects: 395
Study 32751415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastiha Oil
Number of subjects: 0